NVSEF Quote, Financials, Valuation and Earnings

CRISPR Therapeutics AG has a net margin of 28.26% compared to Novartis AG's net margin of -11973.12%. Novartis AG's return on equity of 33.79% beat CRISPR Therapeutics AG's return on equity of -26.17%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -34.85%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 45.32%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.496, which suggesting that the stock is 50.403% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.

Novartis AG has a quarterly dividend of $3.96 per share corresponding to a yield of 3.11%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 67.17% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than CRISPR Therapeutics AG quarterly revenues of $889K. Novartis AG's net income of $3.9B is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, Novartis AG's price-to-earnings ratio is 17.42x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.62x versus 127.66x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines Ltd. has a net margin of 28.26% compared to Novartis AG's net margin of 8.84%. Novartis AG's return on equity of 33.79% beat BeOne Medicines Ltd.'s return on equity of 1.92%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -34.85%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $401.52 which suggests that it could grow by 31.94%. Given that BeOne Medicines Ltd. has higher upside potential than Novartis AG, analysts believe BeOne Medicines Ltd. is more attractive than Novartis AG.

Novartis AG has a beta of 0.496, which suggesting that the stock is 50.403% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.

Novartis AG has a quarterly dividend of $3.96 per share corresponding to a yield of 3.11%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 67.17% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than BeOne Medicines Ltd. quarterly revenues of $1.4B. Novartis AG's net income of $3.9B is higher than BeOne Medicines Ltd.'s net income of $125M. Notably, Novartis AG's price-to-earnings ratio is 17.42x while BeOne Medicines Ltd.'s PE ratio is 585.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.62x versus 6.80x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 28.26% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 33.79% beat Roche Holding AG's return on equity of 28.65%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -34.85%. On the other hand Roche Holding AG has an analysts' consensus of $52.84 which suggests that it could grow by 3.17%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.496, which suggesting that the stock is 50.403% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.97%.

Novartis AG has a quarterly dividend of $3.96 per share corresponding to a yield of 3.11%. Roche Holding AG offers a yield of 2.71% to investors and pays a quarterly dividend of $1.39 per share. Novartis AG pays 67.17% of its earnings as a dividend. Roche Holding AG pays out 58.07% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $3.9B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 17.42x while Roche Holding AG's PE ratio is 30.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.62x versus 4.63x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.